

Jonathan B Angel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8666190/publications.pdf>

Version: 2024-02-01

140
papers

4,493
citations

116194

36
h-index

134545

62
g-index

145
all docs

145
docs citations

145
times ranked

6052
citing authors

#	ARTICLE	IF	CITATIONS
1	Single-dose replicating poxvirus vector-based RBD vaccine drives robust humoral and T cell immune response against SARS-CoV-2 infection. <i>Molecular Therapy</i> , 2022, 30, 1885-1896.	3.7	16
2	Willingness of Older Canadians with HIV to Participate in HIV Cure Research Near and After the End of Life: A Mixed-Method Study. <i>AIDS Research and Human Retroviruses</i> , 2022, 38, 670-682.	0.5	5
3	Salivary Detection of COVID-19. <i>Annals of Internal Medicine</i> , 2021, 174, 131-133.	2.0	64
4	Intravenous administration of Penicillin results in therapeutic intravitreal levels in chronic postoperative endophthalmitis. <i>Journal of Ophthalmic Inflammation and Infection</i> , 2021, 11, 1.	1.2	2
5	Selective killing of human M1 macrophages by Smac mimetics alone and M2 macrophages by Smac mimetics and caspase inhibition. <i>Journal of Leukocyte Biology</i> , 2021, 110, 693-710.	1.5	7
6	LILAC pilot study: Effects of metformin on mTOR activation and HIV reservoir persistence during antiretroviral therapy. <i>EBioMedicine</i> , 2021, 65, 103270.	2.7	46
7	Soluble IL-7/CD127 in Health, Disease, and Its Potential Role as a Therapeutic Agent. <i>ImmunoTargets and Therapy</i> , 2021, Volume 10, 47-62.	2.7	5
8	HIV-Infected Macrophages Are Infected and Killed by the Interferon-Sensitive Rhabdovirus MG1. <i>Journal of Virology</i> , 2021, 95, .	1.5	2
9	Salivary testing of COVID-19: evaluation of serological testing following positive salivary results. <i>BMC Infectious Diseases</i> , 2021, 21, 410.	1.3	3
10	Association between radical cystectomy prophylactic antimicrobial regimen and postoperative infection. <i>Canadian Urological Association Journal</i> , 2021, 15, E644-E651.	0.3	7
11	Identification of novel genes involved in apoptosis of HIV-infected macrophages using unbiased genome-wide screening. <i>BMC Infectious Diseases</i> , 2021, 21, 655.	1.3	0
12	TLR-4 Agonist Induces IFN- γ Production Selectively in Proinflammatory Human M1 Macrophages through the PI3K-mTOR and JNK-MAPK Activated p70S6K Pathway. <i>Journal of Immunology</i> , 2021, 207, 2310-2324.	0.4	15
13	Selective Induction of Cell Death in Human M1 Macrophages by Smac Mimetics Is Mediated by cIAP-2 and RIPK-1/3 through the Activation of mTORC. <i>Journal of Immunology</i> , 2021, 207, 2359-2373.	0.4	5
14	Soluble CD127 potentiates IL-7 activity in vivo in healthy mice. <i>Immunity, Inflammation and Disease</i> , 2021, 9, 1798-1808.	1.3	5
15	Antimicrobial Peptide, LL-37, And Its Potential As An Anti-HIV Agent. <i>Clinical and Investigative Medicine</i> , 2021, 44, E64-71.	0.3	4
16	Role of RIPK1 in SMAC mimetics-induced apoptosis in primary human HIV-infected macrophages. <i>Scientific Reports</i> , 2021, 11, 22901.	1.6	4
17	SMAC Mimetics as Therapeutic Agents in HIV Infection. <i>Frontiers in Immunology</i> , 2021, 12, 780400.	2.2	10
18	CTN 328: immunogenicity outcomes in people living with HIV in Canada following vaccination for COVID-19 (HIV-COV): protocol for an observational cohort study. <i>BMJ Open</i> , 2021, 11, e054208.	0.8	7

#	ARTICLE	IF	CITATIONS
19	Lentiviral Infections Persist in Brain despite Effective Antiretroviral Therapy and Neuroimmune Activation. <i>MBio</i> , 2021, 12, e0278421.	1.8	19
20	IL-7 induces sCD127 release and mCD127 downregulation in human CD8 ⁺ T cells by distinct yet overlapping mechanisms, both of which are impaired in HIV infection. <i>European Journal of Immunology</i> , 2020, 50, 1537-1549.	1.6	5
21	Vedolizumab treatment across antiretroviral treatment interruption in chronic HIV infection: the HAVARTI protocol for a pilot dose-ranging clinical trial to assess safety, tolerance, immunological and virological activity. <i>BMJ Open</i> , 2020, 10, e041359.	0.8	0
22	Vedolizumab treatment across antiretroviral treatment interruption in chronic HIV infection: the HAVARTI protocol for a pilot dose-ranging clinical trial to assess safety, tolerance, immunological and virological activity. <i>BMJ Open</i> , 2020, 10, e041359.	0.8	1
23	Getting to the Heart of the Matter: A Review of Drug Interactions Between HIV Antiretrovirals and Cardiology Medications. <i>Canadian Journal of Cardiology</i> , 2019, 35, 326-340.	0.8	19
24	Beau's lines with onychomadesis in convalescence of invasive pneumococcal disease. <i>Oxford Medical Case Reports</i> , 2019, 2019, omz098.	0.2	0
25	Direct-Acting Antiviral Treatment of HCV Infection Does Not Resolve the Dysfunction of Circulating CD8 ⁺ T-Cells in Advanced Liver Disease. <i>Frontiers in Immunology</i> , 2019, 10, 1926.	2.2	41
26	Sperm can act as vectors for HIV-1 transmission into vaginal and cervical epithelial cells. <i>American Journal of Reproductive Immunology</i> , 2019, 82, e13129.	1.2	7
27	Effect of metformin on the size of the HIV reservoir in non-diabetic ART-treated individuals: single-arm non-randomised Lilac pilot study protocol. <i>BMJ Open</i> , 2019, 9, e028444.	0.8	39
28	Medical Assistance in Death as a Unique Opportunity to Advance Human Immunodeficiency Virus Cure Research. <i>Clinical Infectious Diseases</i> , 2019, 69, 1063-1067.	2.9	13
29	IL-7-induced proliferation of peripheral Th17 cells is impaired in HAART-controlled HIV infection. <i>Aids</i> , 2019, 33, 985-991.	1.0	7
30	clAP1/2-TRAF2-SHP-1-MyD88 Complex Regulates Lipopolysaccharide-Induced IL-27 Production through NF- κ B Activation in Human Macrophages. <i>Journal of Immunology</i> , 2018, 200, 1593-1606.	0.4	19
31	The Oncolytic Virus MG1 Targets and Eliminates Cells Latently Infected With HIV-1: Implications for an HIV Cure. <i>Journal of Infectious Diseases</i> , 2018, 217, 721-730.	1.9	4
32	Antimicrobial peptide LL-37 and its truncated forms, GI-20 and GF-17, exert spermicidal effects and microbicidal activity against <i>Neisseria gonorrhoeae</i> . <i>Human Reproduction</i> , 2018, 33, 2175-2183.	0.4	14
33	Introduction to the Special Issue: HIV Evasion of the Antiviral Response. <i>Cytokine and Growth Factor Reviews</i> , 2018, 40, 1-2.	3.2	0
34	HIV Cure Research: An example of successful advocacy by scientists for science. <i>Clinical and Investigative Medicine</i> , 2018, 41, 14-16.	0.3	0
35	Exploring the Factors Considered by People Living with HIV and Their Partners during Preconception. <i>Journal of the International Association of Providers of AIDS Care</i> , 2017, 16, 239-246.	0.6	4
36	Impairment of the type I interferon response by HIV-1: Potential targets for HIV eradication. <i>Cytokine and Growth Factor Reviews</i> , 2017, 37, 1-16.	3.2	34

#	ARTICLE	IF	CITATIONS
37	Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. <i>Lancet</i> , The, 2017, 390, 1499-1510.	6.3	391
38	HIV and HIV-Tat inhibit LPS-induced IL-27 production in human macrophages by distinct intracellular signaling pathways. <i>Journal of Leukocyte Biology</i> , 2017, 102, 925-939.	1.5	8
39	IL-23 signaling in Th17 cells is inhibited by HIV infection and is not restored by HAART: Implications for persistent immune activation. <i>PLoS ONE</i> , 2017, 12, e0186823.	1.1	23
40	Dendritic Cell Immunotherapy for HIV-1 Infection Using Autologous HIV-1 RNA. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 72, 31-38.	0.9	71
41	Type I interferon responses are impaired in latently HIV infected cells. <i>Retrovirology</i> , 2016, 13, 66.	0.9	16
42	HIV-1 Immunogen: an overview of almost 30 years of clinical testing of a candidate therapeutic vaccine. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 953-966.	1.4	7
43	Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed Patients. <i>PLoS ONE</i> , 2016, 11, e0148231.	1.1	70
44	Evaluating the efficacy of therapeutic HIV vaccines through analytical treatment interruptions. <i>Journal of the International AIDS Society</i> , 2015, 18, 20497.	1.2	22
45	The Effect of Therapeutic HIV Vaccination With ALVAC-HIV With or Without Remune on the Size of the Viral Reservoir (A CTN 173 Substudy). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 70, 122-128.	0.9	5
46	Complexed soluble IL-7 receptor $\hat{I}\pm$ and IL-7 increase IL-7-mediated proliferation and viability of CD8+ T-cells in vitro. <i>Cellular Immunology</i> , 2015, 293, 122-125.	1.4	17
47	Proteomic Characterization of Pig Sperm Anterior Head Plasma Membrane Reveals Roles of Acrosomal Proteins in ZP3 Binding. <i>Journal of Cellular Physiology</i> , 2015, 230, 449-463.	2.0	32
48	Remodeling of the plasma membrane in preparation for sperm-egg recognition: roles of acrosomal proteins. <i>Asian Journal of Andrology</i> , 2015, 17, 574.	0.8	22
49	Self-Reported Preconception Care of HIV-Positive Women of Reproductive Potential. <i>Journal of the International Association of Providers of AIDS Care</i> , 2014, 13, 424-433.	0.6	16
50	IFN- $\hat{I}3$ -induced IL-27 and IL-27p28 expression are differentially regulated through JNK MAPK and PI3K pathways independent of Jak/STAT in human monocytic cells. <i>Immunobiology</i> , 2014, 219, 1-8.	0.8	37
51	The importance of motherhood in HIV-positive women of reproductive age in Ontario, Canada. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2014, 26, 777-784.	0.6	32
52	Engagement of CD14 Sensitizes Primary Monocytes to IFN- $\hat{I}3$ to Produce IL-12/23p40 and IL-23 Through p38 Mitogen-Activated Protein Kinase and Independent of the Janus Kinase/Signal Transducers and Activators of Transcription Signaling. <i>Journal of Interferon and Cytokine Research</i> , 2013, 33, 434-445.	0.5	1
53	Local phylogenetic analysis identifies distinct trends in transmitted HIV drug resistance: implications for public health interventions. <i>BMC Infectious Diseases</i> , 2013, 13, 509.	1.3	9
54	Circulating endothelial progenitor cells in HIV infection: A systematic review. <i>Trends in Cardiovascular Medicine</i> , 2013, 23, 192-200.	2.3	14

#	ARTICLE	IF	CITATIONS
55	Short Communication: Human Immunodeficiency Virus Rebound in Blood and Seminal Plasma Following Discontinuation of Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 266-269.	0.5	12
56	Jak/STAT and PI3K signaling pathways have both common and distinct roles in IL-7-mediated activities in human CD8+ T cells. <i>Journal of Leukocyte Biology</i> , 2013, 95, 117-127.	1.5	23
57	Cyclosporin A and FK506 inhibit IL-12p40 production through the calmodulin/calmodulin-dependent protein kinase-activated phosphoinositide 3-kinase in lipopolysaccharide-stimulated human monocytic cells.. <i>Journal of Biological Chemistry</i> , 2012, 287, 804.	1.6	0
58	In Vitro HIV Type 1 Infection Indirectly Alters CD127 Expression on CD8+ T Cells. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 295-298.	0.5	2
59	HIV-1 Nef inhibits lipopolysaccharide-induced IL-12p40 expression by inhibiting JNK-activated NF κ B in human monocytic cells.. <i>Journal of Biological Chemistry</i> , 2012, 287, 804.	1.6	0
60	Surreptitious Antiretroviral Use as an Explanation for Apparent Elite HIV Control. <i>AIDS Patient Care and STDs</i> , 2012, 26, 645-646.	1.1	0
61	Correction: IL-10 Regulation by HIV-Tat in Primary Human Monocytic Cells: Involvement of Calmodulin/Calmodulin-Dependent Protein Kinase-Activated p38 MAPK and Sp-1 and CREB-1 Transcription Factors. <i>Journal of Immunology</i> , 2012, 188, 3553-3553.	0.4	3
62	The influence of HIV on CD127 expression and its potential implications for IL-7 therapy. <i>Seminars in Immunology</i> , 2012, 24, 231-240.	2.7	31
63	Expression of α chain cytokine receptors on CD8 + T cells in HIV infection with a focus on IL γ (CD127). <i>Immunology and Cell Biology</i> , 2012, 90, 379-387.	1.0	4
64	Optimizing the efficiency of therapeutic HIV vaccine trials: A case for CTN 173. <i>Trials in Vaccinology</i> , 2012, 1, 21-26.	1.2	3
65	Circulating Endothelial Progenitor Cell Levels Are Not Reduced in HIV-Infected Men. <i>Journal of Infectious Diseases</i> , 2012, 205, 713-717.	1.9	18
66	HIV Knowledge Among Canadian-Born and Sub-Saharan African-Born Patients Living with HIV. <i>Journal of Immigrant and Minority Health</i> , 2012, 14, 132-139.	0.8	21
67	Parkinson's disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures. <i>Journal of Neural Transmission</i> , 2011, 118, 795-808.	1.4	230
68	HIV infection of thymocytes inhibits IL-7 activity without altering CD127 expression. <i>Retrovirology</i> , 2011, 8, 72.	0.9	8
69	A randomized controlled trial of HIV therapeutic vaccination using ALVAC with or without Remune. <i>Aids</i> , 2011, 25, 731-739.	1.0	41
70	ALVAC-HIV as a prophylactic and therapeutic vaccine: highlights from over a decade of clinical trials. <i>Future Virology</i> , 2011, 6, 1481-1492.	0.9	0
71	Discontinuation of <i>Pneumocystis jirovecii</i> Pneumonia Prophylaxis with CD4 Count \leq 200 Cells/ μ L and Virology Suppression: A Systematic Review. <i>PLoS ONE</i> , 2011, 6, e28570.	1.1	26
72	Interleukin α 4 downregulates CD127 expression and activity on human thymocytes and mature CD8 + T cells. <i>European Journal of Immunology</i> , 2010, 40, 1396-1407.	1.6	17

#	ARTICLE	IF	CITATIONS
73	Interleukin-7 enhances memory CD8 ⁺ T cell recall responses in health but its activity is impaired in human immunodeficiency virus infection. <i>Immunology</i> , 2010, 131, 525-536.	2.0	18
74	Soluble IL-7R α (sCD127) Inhibits IL-7 Activity and Is Increased in HIV Infection. <i>Journal of Immunology</i> , 2010, 184, 4679-4687.	0.4	84
75	Disparate Regulation of LPS-Induced MAPK Signaling and IL-12p40 Expression Between Different Myeloid Cell Types with and without HIV Infection. <i>Viral Immunology</i> , 2010, 23, 17-28.	0.6	4
76	Patients with Discordant Responses to Antiretroviral Therapy Have Impaired Killing of HIV-Infected T Cells. <i>PLoS Pathogens</i> , 2010, 6, e1001213.	2.1	21
77	Altruism motivates participation in a therapeutic HIV vaccine trial (CTN 173). <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2010, 22, 1403-1409.	0.6	40
78	Cardiovascular complications of Salmonella enteritidis infection. <i>Canadian Journal of Cardiology</i> , 2010, 26, e323-e325.	0.8	23
79	IL-7-dependent STAT-5 activation and CD8 ⁺ T cell proliferation are impaired in HIV infection. <i>Journal of Leukocyte Biology</i> , 2010, 89, 499-506.	1.5	25
80	Canadian Consensus Guidelines for the Optimal Use of Etravirine in the Treatment of HIV-Infected Adults. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2009, 20, e24-e34.	0.7	1
81	Fertility Desires and Intentions of HIV-Positive Women of Reproductive Age in Ontario, Canada: A Cross-Sectional Study. <i>PLoS ONE</i> , 2009, 4, e7925.	1.1	131
82	Optimal Use of Raltegravir (Isentress $\text{\textcircled{R}}$) in the Treatment of HIV-Infected Adults â€“ Canadian Consensus Guidelines. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2009, 20, e67-e80.	0.7	1
83	HIV-1 Nef Inhibits Lipopolysaccharide-induced IL-12p40 Expression by Inhibiting JNK-activated NF κ B in Human Monocytic Cells. <i>Journal of Biological Chemistry</i> , 2009, 284, 7578-7587.	1.6	8
84	Development of a Quantitative Bead Capture Assay for Soluble IL-7 Receptor Alpha in Human Plasma. <i>PLoS ONE</i> , 2009, 4, e6690.	1.1	13
85	Virologic and immunologic activity of PegIntron in HIV disease. <i>Aids</i> , 2009, 23, 2431-2438.	1.0	4
86	IL-2 receptor α chain cytokines differentially regulate human CD8 ⁺ CD127 ⁺ and CD8 ⁺ CD127 ⁻ T cell division and susceptibility to apoptosis. <i>International Immunology</i> , 2009, 21, 29-42.	1.8	15
87	IFN- γ induces IL-23 expression in primary human monocytes via the p38 mitogen activated protein kinase independently of the JAK/STAT signalling. <i>Cytokine</i> , 2009, 48, 99-100.	1.4	0
88	CpG increases vaccine antigen-specific cell-mediated immunity when administered with hepatitis B vaccine in HIV infection. <i>Journal of Immune Based Therapies and Vaccines</i> , 2008, 6, 4.	2.4	26
89	Phase II Study of Vicriviroc versus Efavirenz (both with Zidovudine/Lamivudine) in Treatment-naïve Subjects with HIV-1 Infection. <i>Journal of Infectious Diseases</i> , 2008, 198, 1113-1122.	1.9	71
90	Early Changes in T-Cell Activation Predict Antiretroviral Success in Salvage Therapy of HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 48, 149-155.	0.9	10

#	ARTICLE	IF	CITATIONS
91	Withdrawal of Pneumocystis prophylaxis: authors' reply. <i>Aids</i> , 2008, 22, 324.	1.0	0
92	Cyclosporin A and FK506 Inhibit IL-12p40 Production through the Calmodulin/Calmodulin-dependent Protein Kinase-activated Phosphoinositide 3-Kinase in Lipopolysaccharide-stimulated Human Monocytic Cells. <i>Journal of Biological Chemistry</i> , 2007, 282, 13351-13362.	1.6	29
93	IL-7 decreases IL-7 receptor \hat{A} (CD127) expression and induces the shedding of CD127 by human CD8+ T cells. <i>International Immunology</i> , 2007, 19, 1329-1339.	1.8	76
94	IL-10 Regulation by HIV-Tat in Primary Human Monocytic Cells: Involvement of Calmodulin/Calmodulin-Dependent Protein Kinase-Activated p38 MAPK and Sp-1 and CREB-1 Transcription Factors. <i>Journal of Immunology</i> , 2007, 178, 798-807.	0.4	70
95	Development and Validation of the HIV Medication Readiness Scale. <i>Assessment</i> , 2007, 14, 408-416.	1.9	42
96	Mitigation of antiretroviral-induced hyperlipidemia by hepatitis C virus co-infection. <i>Aids</i> , 2007, 21, 71-76.	1.0	21
97	<i>Pneumocystis jirovecii</i> pneumonia prophylaxis is not required with a CD4+ T-cell count \leq 200 cells/ μ l when viral replication is suppressed. <i>Aids</i> , 2007, 21, 1711-1715.	1.0	48
98	Effect of a four-week course of interleukin-10 on cytokine production in a placebo-controlled study of HIV-1-infected subjects. <i>European Cytokine Network</i> , 2007, 18, 49-58.	1.1	6
99	External Quality Assessment of <i>HLA-B*5701</i> Reporting: An International Multicentre Survey. <i>Antiviral Therapy</i> , 2007, 12, 1027-1032.	0.6	40
100	Effects of Highly Active Antiretroviral Therapy and Immune Recovery on CD8+ T-Cell-Mediated Inhibition of HIV-1 Transcription. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 43, 393-400.	0.9	0
101	Long-Term Follow-up of a Cohort of HIV-Infected Patients Who Discontinued Maintenance Therapy for Cytomegalovirus Retinitis. <i>HIV Clinical Trials</i> , 2006, 7, 1-9.	2.0	15
102	Optimization of culture and storage conditions for an in vitro system to evaluate thymocyte phenotype and function. <i>Journal of Immunological Methods</i> , 2006, 312, 157-166.	0.6	10
103	Intracellular HIV-Tat Expression Induces IL-10 Synthesis by the CREB-1 Transcription Factor through Ser133Phosphorylation and Its Regulation by the ERK1/2 MAPK in Human Monocytic Cells. <i>Journal of Biological Chemistry</i> , 2006, 281, 31647-31658.	1.6	46
104	Differential Regulation of CXCR4 and CCR5 Expression by Interleukin (IL)-4 and IL-13 Is Associated with Inhibition of Chemotaxis and Human Immunodeficiency Virus (HIV) Type 1 Replication But Not HIV Entry into Human Monocytes. <i>Viral Immunology</i> , 2006, 19, 409-423.	0.6	20
105	Granulocyte-macrophage colony-stimulating factor as an immune-based therapy in HIV infection. <i>Journal of Immune Based Therapies and Vaccines</i> , 2005, 3, 3.	2.4	13
106	Reactivation of Hepatitis B Infection following Allogeneic Bone Marrow Transplantation in a Hepatitis B-Immune Patient: Case Report and Review of the Literature. <i>Clinical Infectious Diseases</i> , 2005, 41, 1277-1282.	2.9	71
107	CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. <i>Aids</i> , 2005, 19, 1473-1479.	1.0	173
108	<i>Mycobacterium abscessus</i> infection after use of tumor necrosis factor $\hat{\pm}$ inhibitor therapy: case report and review of infectious complications associated with tumor necrosis factor $\hat{\pm}$ inhibitor use. <i>Diagnostic Microbiology and Infectious Disease</i> , 2005, 53, 233-238.	0.8	47

#	ARTICLE	IF	CITATIONS
109	Association of the Frequency of Respiratory Illness in Early Childhood with a Change in the Distribution of Blood Lymphocyte Subpopulations. <i>Allergy, Asthma and Clinical Immunology</i> , 2005, 01, 135.	0.9	0
110	Antiretroviral therapy influences cellular susceptibility to apoptosis in vivo. <i>Frontiers in Bioscience - Landmark</i> , 2004, 9, 338.	3.0	11
111	The Efficacy of Calcium Carbonate in the Treatment of Protease Inhibitor-Induced Persistent Diarrhea in HIV-Infected Patients. <i>HIV Clinical Trials</i> , 2004, 5, 19-24.	2.0	11
112	Virological evaluation of the "Ottawa case"™ indicates no evidence for HIV-1 superinfection. <i>Aids</i> , 2004, 18, 331-334.	1.0	9
113	Dexamethasone Inhibits IL-12p40 Production in Lipopolysaccharide-Stimulated Human Monocytic Cells by Down-Regulating the Activity of c-Jun N-Terminal Kinase, the Activation Protein-1, and NF- κ B Transcription Factors. <i>Journal of Immunology</i> , 2004, 172, 318-330.	0.4	121
114	Nef Protein of Human Immunodeficiency Virus and Lipopolysaccharide Induce Expression of CD14 on Human Monocytes through Differential Utilization of Interleukin-10. <i>Vaccine Journal</i> , 2002, 9, 1212-1221.	3.2	11
115	Normalization of natural killer cell function and phenotype with effective anti-HIV therapy and the role of IL-10. <i>Aids</i> , 2002, 16, 1251-1256.	1.0	71
116	Hepatotoxicity Associated with Antiretroviral Therapy Containing Dual versus Single Protease Inhibitors in Individuals Coinfected with Hepatitis C Virus and Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2002, 34, 1259-1263.	2.9	66
117	Active cellular infection of myeloid cells is required for HIV-1-mediated suppression of interleukin-12 p40 expression. <i>Cellular Immunology</i> , 2002, 215, 120-132.	1.4	13
118	Characteristics of Hepatitis C Virus Infection in HIV-Infected People. <i>Canadian Journal of Infectious Diseases & Medical Microbiology</i> , 2001, 12, 157-163.	0.3	1
119	Interleukin-7 Receptor Expression on CD8 + T Cells Is Reduced in HIV Infection and Partially Restored With Effective Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001, 28, 454-457.	0.9	109
120	An argument for routine therapeutic drug monitoring of HIV-1 protease inhibitors during pregnancy. <i>Aids</i> , 2001, 15, 417-419.	1.0	28
121	A multicenter, randomized, double-blind, placebo-controlled trial of recombinant human interleukin-10 in HIV-infected subjects. <i>Aids</i> , 2000, 14, 2503-2508.	1.0	23
122	Phase III study of granulocyte-macrophage colony-stimulating factor in advanced HIV disease: effect on infections, CD4 cell counts and HIV suppression. <i>Aids</i> , 2000, 14, 387-395.	1.0	42
123	Ritonavir increases the level of active ADD-1/SREBP-1 protein during adipogenesis. <i>Aids</i> , 2000, 14, 2467-2473.	1.0	65
124	Decreased HIV-Associated T Cell Apoptosis by HIV Protease Inhibitors. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 559-567.	0.5	97
125	Acute monoarthritis complicating therapy with indinavir. <i>Aids</i> , 2000, 14, 2064.	1.0	9
126	Development of Kaposi's Sarcoma Despite Sustained Suppression of HIV Plasma Viremia. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 1999, 22, 209.	0.9	19

#	ARTICLE	IF	CITATIONS
127	Sustained Suppression of Plasma HIV RNA Is Associated with an Increase in the Production of Mitogen-Induced MIP-1alpha and MIP-1beta. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 1073-1077.	0.5	20
128	Dynamic correlation of apoptosis and immune activation during treatment of HIV infection. <i>Cell Death and Differentiation</i> , 1999, 6, 420-432.	5.0	94
129	Acute phase responses and cytokine secretion in chronic fatigue syndrome. <i>Journal of Clinical Immunology</i> , 1999, 19, 414-421.	2.0	69
130	Ritonavir and saquinavir combination therapy for the treatment of HIV infection. <i>Aids</i> , 1999, 13, 213-224.	1.0	176
131	Development of Kaposi's Sarcoma Despite Sustained Suppression of HIV Plasma Viremia. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 1999, 22, 209.	0.9	20
132	Hormonal influences on stress-induced neutrophil mobilization in health and chronic fatigue syndrome. <i>Journal of Clinical Immunology</i> , 1998, 18, 291-298.	2.0	24
133	Protease inhibitors and adipocyte differentiation in cell culture. <i>Lancet, The</i> , 1998, 352, 1032.	6.3	45
134	Development of Cervical Fat Pads Following Therapy with Human Immunodeficiency Virus Type 1 Protease Inhibitors. <i>Clinical Infectious Diseases</i> , 1998, 27, 65-67.	2.9	108
135	Effect of Antiretroviral Therapy and Viral Load on the Perceived Risk of HIV Transmission and the Need for Safer Sexual Practices. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1998, 19, 124-129.	0.3	68
136	Vaccine-Associated Measles Pneumonitis in an Adult with AIDS. <i>Annals of Internal Medicine</i> , 1998, 129, 104.	2.0	92
137	Interleukin-1 beta, interleukin-1 receptor antagonist, and soluble interleukin-1 receptor type II secretion in chronic fatigue syndrome. <i>Journal of Clinical Immunology</i> , 1997, 17, 253-261.	2.0	59
138	Clinical, hematologic, and immunologic effects of interleukin-10 in humans. <i>Journal of Clinical Immunology</i> , 1996, 16, 291-303.	2.0	85
139	Soluble Tumor Necrosis Factor Receptors Inhibit Phorbol Myristate Acetate and Cytokine-Induced HIV-1 Expression Chronically Infected U1 Cells. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1996, 11, 430-437.	0.3	7
140	Rolipram, a specific type IV phosphodiesterase inhibitor, is a potent inhibitor of HIV-1 replication. <i>Aids</i> , 1995, 9, 1137-1144.	1.0	33